WO1988009165A1 - Injectable opacifying liposome composition - Google Patents

Injectable opacifying liposome composition Download PDF

Info

Publication number
WO1988009165A1
WO1988009165A1 PCT/EP1988/000447 EP8800447W WO8809165A1 WO 1988009165 A1 WO1988009165 A1 WO 1988009165A1 EP 8800447 W EP8800447 W EP 8800447W WO 8809165 A1 WO8809165 A1 WO 8809165A1
Authority
WO
WIPO (PCT)
Prior art keywords
vesicles
liposomes
iodine
encapsulated
suspension
Prior art date
Application number
PCT/EP1988/000447
Other languages
English (en)
French (fr)
Inventor
Michel Schneider
Hervé Tournier
Bernard Lamy
Original Assignee
Bracco Industria Chimica S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4223355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1988009165(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bracco Industria Chimica S.P.A. filed Critical Bracco Industria Chimica S.P.A.
Priority to AT88904952T priority Critical patent/ATE80294T1/de
Priority to DE3874485T priority patent/DE3874485T3/de
Priority to EP88904952A priority patent/EP0314764B2/en
Priority to US07/302,690 priority patent/US5312615A/en
Publication of WO1988009165A1 publication Critical patent/WO1988009165A1/en
Priority to US08/440,134 priority patent/US5626832A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles

Definitions

  • Injectable opacifying liposome composition Injectable opacifying liposome composition.
  • the present invention relates to an aqueous composition which can he injected into the circulatory system of a patient and the purpose of which is to opacity certain organs with a view to their diagnostic examination with X-rays.
  • This composition is formed of a suspension, in a physiologically acceptable aqueous medium, of liposomes as vesicles with a phospholipidic membrane containing, encapsulated in these vesicles, an aqueous solution of at least one iodinated compound which is opaque to the X-rays.
  • suspensions oi liposomes as vehicles for the transportation, in certain organs which are to be studied, of opacifying agents intended for radioscopic examinations.
  • the specification or US-A-4,192,859 describes such a suspension of liposomes constituted of lecithin and sterols and containing about 20 to 60% by weight of a contrast agent intended for the examination ol organs, particularly of organs in relation with the reti culoendothelial and cardiovascular systems, as well as lymphographic examinations.
  • contrast agents the following compounds are referred to in this specification:
  • the lipidic membrane of the liposomes which are used in accordance with this document mainly contains phospholipids, a sterol, lecithin, dicetyl phosphate or stearyl amine, and an organic solvent.
  • an organic solvent such as chloroform, dichloromethane, ethyl ether, carbon tetrachloride, ethyl acetate, dioxane, THF, etc. After having evaporated the volatile compounds under reduced pressure, the lipidic mixture is dispersed in a buffering solution containing a measured quantity of an opacifying agent.
  • the whole is then stirred for several hours, this causing the formation of liposomes, a part of the dispersion liquid (containing the opacifying agent) then being encapsulated in the liposomic vesicles which are thus produced.
  • the dispersion is then subjected to a sonication in order to reduce the size of these liposomes and the viscosity of the dispersion.
  • FR-A-2, 561, 101 describes a process for the preparation of liposomes which may contain X-ray opacifying agents.
  • this specification there are first of all prepared "precursors" of liposomes in organic solution, from which then the solvent is partially separated, this solution containing a proportion of lipids which are adapted to convert the monomolecular membrane of the precursors into bimolecular membrane. This solution is then dispersed in an aqueous medium and the residual solvent is completely eliminated.
  • GB-A-134,869 describes a technique tor the preparation of liposomes, in accordance with which particles (10 ⁇ m) of a hydrosoluble carrier agent (NaCl, saccharose, lactose, etc.) are coated with an amphipatic agent, the subsequent dissolution of the carrier in an aqueous medium yielding the liposomes.
  • the coating is effected by dispersing the solid particles of the carrier in an organic solution of the lipid and of the product to be encapsulated, among which are found the X-contrast agents.
  • the amphipatic agents there are to be mentioned the saturated synthetic lecithins.
  • GB-A-2, 135,268 also describes a process for forming liposomes which may contain opacifiers, starting from particles of a hydrosoluble carrier agent.
  • GB-A-2, 135 ,647 describes a process for the preparation of liposomes which are somewhat similar to that of the two preceding documents, except for the difference that the particles of the carrier material are insoluble.
  • What are involved here are microspheres of glass or synthetic resin. These particles are coated with a film containing a lipid and, optionally, an ionic surfactant or cholesterol, by bringing them into contact with an organic solution of these ingredients, the operation being followed by an evaporation. Thereafter, by agitating these spheres in an aqueous dispersion medium to be encapsulated, more particularly containing an X-ray opacifier, then separating out the latter by filtration or centrifugation, there is obtained the desired solution of liposomes.
  • GR-A-2, 156, 345 describes diacetyl- aminated compounds of triiodobenzoic acid as X-contrast agents and the incorporation thereof into liposomes.
  • GB-A-2, 157, 283 describes compounds which are similar to those of the preceding document and the incorporation thereof, in amounts of 20-60%, into liposomes. The latter are in conformity with the preparation which is described in the specification of US 3,957,971.
  • EP-A-179,660 describes a process for preparing suspensions of liposomes, in accordance with which a bioactive substance to be encapsulated is dispersed in the presence of lipids in organic solution, the solvent is evaporated until there is formation of a gel and this latter is re- dispersed in a second buffering aqueous medium.
  • the liposomic vesicles containing an opacifying agent are finally fixed in the liver and the spleen, it Is also possible for them, with their displacement in the circulatory system, to be retained by the capillaries of the lungs with the risk of fatty embolism.
  • the specific capacity of encapsulation by volume and weight of iodinated products of the actual liposomes is relatively small (usually less than 1 g of iodine per g of lipids), and this necessitates the injection of a relatively large quantity of lipids in order to achieve the desired opacifying effect.
  • the encapsulation capacity of liposomes of the class which he defines as "small unilamellar vesicles, (SUV), which have a diameter between 0.02 and 0.5 ⁇ m, is of the order of 0.2 to 1.5 1/mole, which corresponds, admitting a mean molecular weight of about 800 (phospholipids), to an encapsulation capacity of about 1 to 2 ml/g of phospholipids.
  • SUV small unilamellar vesicles
  • an appreciable part of the iodine which is contained by the present suspensions of liposomes with opacifying capacity is dissolved in the aqueous dispersion phase and not encapsulated within the vesicles (see, for example, the suspensions described in the specification of US-A-4, 192, 859).
  • Such a situation may be found to be undesirable because, at the time of injection for diagnostic purposes, the portion of non-encapsulated iodine is not fixed in the organs to be investigated and does not serve any useful purpose. Consequently, in order to avoid having to inject iodine for nothing, it is desirable to be able to decrease as far as possible this non-encapsulated fraction.
  • composition as defined in the claim 1 permits the disadvantages of lack of encapsulation capacity to be overcome.
  • the present inventors have established to their surprise that, in "normalising" the size of the vesicules of the solution of liposomes in a certain range of values, i.e. by eliminating, by sizing by extrusion, the major part of the vesicles with a dimension below 0.15 ⁇ m or exceeding 3 ⁇ m, and preferably by keeping the major part of the vesicles at a size which is between 0.2 and 1 ⁇ m, the amount of encapsulated iodine was increased in a significant manner.
  • the Index of their polydispersity is not higher than 4- and, preferably, the size of more than 70% of the total number of vesicles of the solution of liposomes is between 0.2 and 2 ⁇ ni. It will hereinafter be seen, in the section concerned with the preparation techniques, what is to be understood by polydispersivity Index.
  • the viscosity of the composition according to the invention which may, in certain forms of execution, be lower than 30 or of the order of 20 to 30 mP.s at 37°C, is clearly lower than that of the suspensions according to the prior art (for instance, the suspensions described in the specification of US-A-4, 192 ,859 may, for iodine contents of 60%, reach viscosities of several hundreds of mP.s.). It is in fact evident that the viscosity of the suspensions of liposomes decreases when the llpid level diminishes and that, to keep the 1/1 ratio constant, it Is necessary to increase to the same extent the encapsulation capacity of these latter.
  • iodinated opacifying agents contributes also to raising the viscosity of the solutions (for example, an aqueous solution of iopamidol at 300 g of iodine per litre has a viscosity of 8.8 mP.s at 20°C and 4.7 mP.s at 37°C) and any diminution of the concentration of the iodinated compound in the dispersion medium of the liposomes will contribute to lowering this viscotiy.
  • the lipidic membrane of the liposomes of the composition according to the invention may be constituted of the amphipa- tic compounds normally employed in the usual practice of liposomic suspensions. Such compounds are described in the aforementioned references. It is preferred to use phospho- lipids, such as the hydrogenated lecithins of soya (for example, the products NC-95H of Nattermann Chemie), dipalmitoyl phosphatidyl choline (DPPC), distearoyl phosphatidyl choline (DSPC), sphingomyeline (SM) dicetylphosphate (DCP), dipalmi- toyl-phosphatidyl glycerol (DPPG) and dipalmitoyl phosphatidic acid (DPPA).
  • soya dipalmitoyl phosphatidyl choline
  • DSPC distearoyl phosphatidyl choline
  • SM sphingomyeline
  • DCP dipalmi
  • the proportion of lipids relatively to the dispersion buffering phase is generally of the order of 0.1 to 10%, preferably about 2 to 6%.
  • the proportion of encapsulated liquid relatively to the lipids (ratio v/1) is not below 5 ml/g and may in exceptional cases reach 20 ml/g. Preferably, it is between 5 and 15 ml/g, and most frequently between 7 and 12 ml/g.
  • opacifiers are more suitable than others as regards the effective encapsulation capacity of their aqueous solutions in the liposomic vesicles and the stability of these vesicles in storage.
  • certain of the opacifying agents in solution are more difficultly encapsulated than others at the time of formation of the liposomes and, moreover, certain of them diffuse more easily than others outside the liposomic membrane, in storage or at the time of handling.
  • the ionic contrast means derived from triiodobenzoic acid, such as, for example, the sodium and/or meglumine salts of diatrizoic acid, and preferably the non-ionic contrast means, such as iopamidol or iomeprol, given as a non-limiting example.
  • the contrast agents are used in aqueous solution form with a concentration which is between 100 and 450 g of iodine/1, preferably of 250 to 380 gl/l. With such solutions, and the composition according to the invention, there are obtained amounts of encapsulated iodine which may be up to 6 g of iodine/g of phospholipid.
  • the volume occupied by the liposomic vesicles represents about 5 to 60% of the total volume of the suspension and may, in certain special cases, exceed these values (up to 70-80%).
  • the procedure is to normalise the size of these vesicles, i.e. to select an important proportion of vesicles of which the size is contained within a given range and eliminate the others, or by some means, to transform these latter (the others) into new vesicles having dimensions which correspond to the chosen range.
  • d W is the size of the p rarticles g ⁇ iven by the apparatus
  • the process as claimed in claim 4 illustrates a means for arriving at a composition such as defined in claim 1. It has in fact been ascertained that these are the liposomes of which the majority of the vesicles have a size which is between about 0.15 and 3 ⁇ m, preferably 0.2 and 1 ⁇ m, which have a particularly high encapsulation capacity. By the term “majority”, it is wished to express the fact that at least 70% of the liposomic vesicles have a diameter conforming to the chosen range.
  • the liposomic vesicles contained in this range have the capacity of integrating such a high volume
  • the liposomes below this limit have an unfavourable volume/surface ration (actually, the more the diameter of a sphere decreases, the smaller this ratio becomes)
  • the vesicles exceeding approximately 2 ⁇ m are often plurilamellar and consequently, the mass of their membrane, for a given capacity, is higher.
  • the plurilamellar liposomes are re-arranged, at least in part, into smaller liposomes having a monolamellar membrane; a large proportion of these "re-arranged" liposomes then corresponds to the optimal dimensions suitable for the composition according to the invention.
  • the normalisation of a solution of liposomes is effected by being forced under pressure through a filtering membrane.
  • the pressures brought into play by this "extrusion" may vary between a fraction of a bar and several bars.
  • membranes having a porosity . which is between about 0.4 and 2 ⁇ m extrusion pressures from 0.5 to 10 bar are used.
  • extrusion pressures from 0.5 to 10 bar are used.
  • the increasing of the 1/1 ratio following the extrusion treatment is produced when the aqueous dispersion phase contains an iodinated opacifying compound in an appreciable proportion. It is evident that if this phase is deprived of iodine, it is not possible to have an increase of the encapsulated iodine by passage of the exterior phase towards the interior of the vesicles.
  • the extrusion temperature plays a part in connection with the concentration of opacifying agents of the solution encapsulated in the vesicles.
  • the extrusion is effected at normal temperature, it is possible to produce a certain diminution of the 1/1 ratio.
  • this constitutes an addditional unexpected element, if one proceeds at a temperature higher than the transition temperature of the phospholipids forming the wall of the liposomes, there is observed an increase in this ratio.
  • temperatures between 50° and 90° are used, for example, in the region of 75°C. It may be imagined that the unexpected result which is observed is due to a softening of the vesicles, caused by the raising of the temperature.
  • ultracentrifugation or ultrafiltration have advantageously been used, these procedures causing a physical separation between the vesicles themselves and the said aqueous phase. Once this separation is achieved, the liposomes are redispersed in a new aqueous dispersion phase.
  • solutions which are compatible with the living tissues and the liquids of the circulatory system.
  • solutions which are compatible with the living tissues and the liquids of the circulatory system.
  • the salt solutions aqueous solutions, buffered or not with Tris, phosphate, etc. (pH in the region of neutrality) and the hypertonic solutions containing one or more substances selected from salt, glucose, opacifying agents, buffering agents, etc.
  • One typical solution 0.8 Osm
  • REV method cf. F. Szoka et al., (1978), Proc. Natl. Acad. Sci. USA 75, 4194
  • EP-A-179.660 cf. F. Szoka et al., (1978), Proc. Natl. Acad. Sci. USA 75, 4194
  • the composition according to the invention As the time of its use as opacifying agent by injection into laboratory animals, the composition according to the invention is shown to be very effective, on account of its specific opacifying power and its selectivity. Particularly observed is a reduction by 30 to 40 times of the retention of iodine in the lungs. It is to be particularly noted that, with the present composition, using a total amount by weight of iodine smaller than 20%, it is possible to obtain diagnostic results equivalent or superior to those obtained with suspensions according to the prior art (see, for example, US-A- 4,192,859), wherein the global concentration of iodine may reach 60% by weight of suspension of liposomes.
  • a solution which contains 57 mg of dipalmitoyl phosphatidic acid (DPPA, Fluka) and 543 mg dipalmitoyl phosphatidyl choline (DPPC, Fluka) In 42 ml of chloroform. To 20 ml of this solution are added 20 ml of chloroform and 40 ml of diisopropyl ether and then, after stirring, 12 ml of a 76% (p/v) aqueous solution of meglumine diatrizoate, an iodinated opacifying agent (Bracco). The mixture obtained, heated to 50°C, was subjected for 5 minutes to ultrasonics (Braun Labsonic 1510).
  • DPPA dipalmitoyl phosphatidic acid
  • DPPC dipalmitoyl phosphatidyl choline
  • the emulsion was then concentrated at 45°C in a rotary evaporator until a gel was obtained.
  • a mixture of about 8 ml of the 76% aqueous solution of meglumine diatrizoate and 4 ml of distilled water was then introduced into the flask and the evaporation was continued with rotation.
  • After obtaining a homogeneous mixture there was again added a mixture of about 20 ml of the solution with 76% of meglumine diatrizoate and 8 ml of distilled water and the last traces of solvents were eliminated by evaporation.
  • the volume of the solution of liposomes as obtained (solution A) was adjusted to 40 ml by means of distilled water.
  • the quantity of meglumine diatrizoate effectively encapsulated within the liposomes was then determined.
  • An aliquot of the preparation obtained (5 ml) was centrifugated for 25 minutes at 235,000 g.
  • the vesicles were taken up in 10 ml of a saline solution (0.9% NaCl, 10 mM TrisHCl, pH 7.2) and then subjected to a second centrifugation operation (15 minutes, 26,000 g). These phases of centrifugation, followed by taking up in suspension, were repeated another four times, this making possible the complete elimination of non-encapsulated meglumine diatrizoate.
  • the remainder of the solution A was brought to 75°C, then extruded under heat through a polycarbonate filter (Nuclepore) with a porosity of 1 micron.
  • the solution obtained was then cooled to ambient temperature and thereafter subjected to a series of centrifugations, followed by being taken up in suspension, as described above.
  • Spectrophotometric analysis of the supernatant liquid obtained after the fifth washing showed a residual iodine concentration in the external phase lower than 0.2 mg/ml.
  • the residue of liposomes was suspended in a total volume of 7 ml of buffer.
  • This purification step (elimination of the iodine dissolved in the dispersive phase) was then repeated a certain number of times with one or other of these solutions, the centrifuging taking place at 26,000 g for 15 minutes, down to a residual iodine content of the dispersion phase below 0.2 mg/ml. This content was measured by spectrophotometry at 260 nm. In general, a number of centrifugation and redispersion stages of four, or less, is sufficient for achieving the desired degree of purification.
  • the quantity of encapsulated iodine was determined as described in example 1, by treatment of an aliquot quantity with sodium dodecyl-sulphate (SDS): 0.1 ml of 10% aqueous SDS is added to 0.9 ml of the solution of liposomes, and the mixture is heated for 5 minutes at 40°C, then the spectrophotometric reading is taken (the control being an identical sample without encapsulated iodine).
  • the optical density corresponding to 1 ⁇ g of iodine/ml of solution is 0.054 at 260 nm.
  • a particle counter COULTER Nanosizer
  • the results appear in the following table.
  • the tests 1 and 2 concern samples of suspensions in a saline solution; the tests 3 concern suspensions in glucose medium.
  • This mixture was then subjected to five centrifuging operations in succession (one at 235,000 g for 30 minutes, followed by four at 29,000 g for 30 minutes at 4°C), each of these centrifuging operations being followed by the residue being resuspended in a saline solution (NaCl 0.9%, Tris-HCl 10 mM, pH 7.2). There was thereafter determined, spectrophotometrically at 260 nm (see the preceding example), the residual concentration of iopamidol in the wash-waters of the last washing operation, and also that of the encapsulated solution after rupturing of the liposomic vesicles by sodium dodecyl-sulphate (SDS).
  • SDS sodium dodecyl-sulphate
  • the preparation of the liposomes as described above was repeated so as to obtain, in total, 375 ml of suspension containing 7.7 mg of encapsulated iodine per ml and 5.5 mg of lipids per ml (ratio of iodine/phospholipids 1.39).
  • This preparation was then subjected to a diafiltration at 10°C with the aid of a microf iltration module (type MD 020 CP2N, porosity of 0.2 ⁇ m, ENKA, Wuppertal, German Federal Republic), the volume of liquid passing through the membrane and eliminated in the filtrate being continually replaced by addition in the suspension of liposomes of a fresh saline solution (NaCl 0.9%, Tris-HCl 10 mM pH 7.2). After elimination of 1.5 1 of filtrate, the diafiltrateed solution was concentrated, this yielding 97 ml of microfiltered liposomes, the majority of the vesicles of a size smaller than 0.2 ⁇ m having been eliminated.
  • a microf iltration module type MD 020 CP2N, porosity of 0.2 ⁇ m, ENKA, Wuppertal, German Federal Republic
  • this preparation contains 24.9 mg of encapsulated iodine per ml and 16.4 mg of lipids per ml, i.e., a ratio of encapsulated iodine/phospholipids of 1.52.
  • the microfiltration has thus made it possible to increase the encapsulated iodine/phospholipid concentration from 1.39 to 1.52, i.e. an increase of about 9%.
  • lipids lipids
  • iodine solution 300 mg/ml
  • iopamidol 8 mM Tris buffering agent, pH 7.2, 10 -3 M disodium EDTA, this solution being filtered beforehand through filters of 0.45 ⁇ m.
  • the next step was the injection of this suspension into four groups of Sprague-Dawley rats (five animals in each group) at the rate of 250 mg of iodine per kg.
  • the animals were killed, in groups, after 30 minutes, 1 hour, 4 hours and 24 hours and the blood was collected and conserved in heparinized tubes.
  • the organs (livers, spleens, kidneys and lungs) were removed beforehand and weighed. Aliquot amounts of these organs weere homogenized in 7 mM ammonia (5 ml) in order to determine the quantity of residual blood in accordance with the method described by MEIJER et al. (Clin. Chim. Acta (1962), 2, 638)
  • the corrected results for the blood content appear in the following table and also comprise measurements carried out on untreated animals.
  • liposomes which are prepared as de ⁇ cirbed in example 4 (specimen E-08) were injected intravenously in the dosage of 250 mg of iodine/kg to Sprague-Dawley rats which had been subjected to a computerized tomographic examination of the liver, before and after the injection.
  • the images were recorded before the injection of the suspension of liposomes, then 5', 10', 15', 30', 60', 90', 2 h, 3 h and 4 h after the injection, and there was observed an increase in contrast of the liver, expressed in llounsfield Units (HU), this increase being between 50% and 130% during the period which is between 30 minutes and 4 hours.
  • HU llounsfield Units
  • DCP dicetyl-phosphate
  • DPPG dipalmitoyl-phosphatidyl glycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/EP1988/000447 1987-05-22 1988-05-16 Injectable opacifying liposome composition WO1988009165A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AT88904952T ATE80294T1 (de) 1987-05-22 1988-05-16 Injizierbare, opazifizierende liposomzusammensetzung.
DE3874485T DE3874485T3 (de) 1987-05-22 1988-05-16 Injizierbare, opazifizierende liposomzusammensetzung.
EP88904952A EP0314764B2 (en) 1987-05-22 1988-05-16 Injectable opacifying liposome composition
US07/302,690 US5312615A (en) 1987-05-22 1988-05-16 Injectable opacifying composition containing liposomes of high encapsulation capacity for X-ray examinations
US08/440,134 US5626832A (en) 1987-05-22 1995-05-12 Injectable opacifying composition containing liposomes of high encapsulation capacity for X-ray examinations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH1991/87A CH672733A5 (US06403056-20020611-C00020.png) 1987-05-22 1987-05-22
CH1991/87-3 1987-05-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US08/128,206 Continuation US5445810A (en) 1987-05-22 1993-09-29 Injectable opacifying composition containing liposomes of high encapsulating capacity for X-ray examinations

Publications (1)

Publication Number Publication Date
WO1988009165A1 true WO1988009165A1 (en) 1988-12-01

Family

ID=4223355

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1988/000447 WO1988009165A1 (en) 1987-05-22 1988-05-16 Injectable opacifying liposome composition

Country Status (13)

Country Link
US (3) US5312615A (US06403056-20020611-C00020.png)
EP (1) EP0314764B2 (US06403056-20020611-C00020.png)
JP (1) JP2619037B2 (US06403056-20020611-C00020.png)
AT (1) ATE80294T1 (US06403056-20020611-C00020.png)
AU (1) AU612371B2 (US06403056-20020611-C00020.png)
CA (1) CA1303978C (US06403056-20020611-C00020.png)
CH (1) CH672733A5 (US06403056-20020611-C00020.png)
DE (1) DE3874485T3 (US06403056-20020611-C00020.png)
ES (1) ES2009917A6 (US06403056-20020611-C00020.png)
IL (1) IL86409A (US06403056-20020611-C00020.png)
MX (1) MX9203271A (US06403056-20020611-C00020.png)
WO (1) WO1988009165A1 (US06403056-20020611-C00020.png)
ZA (1) ZA883449B (US06403056-20020611-C00020.png)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010166A1 (en) * 1990-12-11 1992-06-25 Sintetica S.A. Method for making liposomes of enhanced entrapping capacity toward foreign substances to be encapsulated
WO1992021384A1 (en) * 1991-06-03 1992-12-10 Karlshamns Lipidteknik Ab X-ray contrast agent
US5271928A (en) * 1990-04-02 1993-12-21 Sintetica S.A. Stable microbubbles suspensions injectable into living organisms
WO1996025955A1 (en) * 1995-02-24 1996-08-29 Bracco Research S.A. Liposome suspensions as blood pool imaging contrast agents
WO1996035429A1 (de) * 1995-05-10 1996-11-14 Schering Aktiengesellschaft Verwendung nichtsteroidaler entzündungshemmer zur verbesserung der physiologischen verträglichkeit partikulärer pharmazeutischer zubereitungen
US5614214A (en) * 1993-05-21 1997-03-25 The Liposome Company, Inc. Reduction of liposome-induced adverse physiological reactions
US5676928A (en) * 1994-03-28 1997-10-14 Nycomed Imaging As Liposomes
WO2000011007A1 (en) * 1998-08-19 2000-03-02 Bracco Research S.A. Carboxylated phosphatidic acid esters
US6217849B1 (en) 1993-09-29 2001-04-17 Bracco Research S.A. Liposome suspensions as blood pool imaging contrast agents
US6613306B1 (en) * 1990-04-02 2003-09-02 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
EP1742669A1 (en) * 2004-04-21 2007-01-17 Marvel Therapeutics Compositions and methods for enhancing contrast in imaging
WO2007129311A2 (en) * 2006-05-04 2007-11-15 Pan Sci Tech S.A. Nano-particles with contrast agents for diagnostic delivery system for x-ray and ct
US7297344B1 (en) 1999-05-27 2007-11-20 Euro-Celtique, S.A. Preparations for the promotion of wound healing in the upper respiratory tract and/or ear
US7300667B1 (en) 1999-05-27 2007-11-27 Euro-Celtique, S.A. Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract
US7468194B1 (en) 1999-05-27 2008-12-23 Euro-Celtique, S.A. Preparations for the application of anti-inflammatory agents
US7588751B2 (en) * 2004-07-21 2009-09-15 Konica Minolta Medical & Graphic, Inc. Liposome-containing radiographic contrast medium and preparation method thereof
EP2279757A2 (en) 2000-06-02 2011-02-02 Bracco Suisse SA Compounds for targeting endothelial cells
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
US8480952B2 (en) * 2004-08-11 2013-07-09 Konica Minolta Medical & Graphic, Inc. Method of manufacturing pharmaceutical preparations containing liposomes
US8642013B2 (en) 2007-12-05 2014-02-04 Ananth Annapragada Nano-scale contrast agents and methods of use
EP2410990A4 (en) * 2009-03-19 2015-05-20 Marval Biosciences Inc COMPOSITIONS AND METHODS FOR CONTRAST GAINING IN IMAGING
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH672733A5 (US06403056-20020611-C00020.png) * 1987-05-22 1989-12-29 Bracco Ind Chimica Spa
MX9203504A (es) * 1988-04-20 1992-07-01 Liposome Co Inc Complejo agente: lipido activo de alta proporcion.
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5820848A (en) * 1990-01-12 1998-10-13 The Liposome Company, Inc. Methods of preparing interdigitation-fusion liposomes and gels which encapsulate a bioactive agent
US5578292A (en) 1991-11-20 1996-11-26 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US7083778B2 (en) * 1991-05-03 2006-08-01 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US5445813A (en) * 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
US20010024638A1 (en) * 1992-11-02 2001-09-27 Michel Schneider Stable microbubble suspensions as enhancement agents for ultrasound echography and dry formulations thereof
US6989141B2 (en) * 1990-05-18 2006-01-24 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
USRE39146E1 (en) 1990-04-02 2006-06-27 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US20040208826A1 (en) * 1990-04-02 2004-10-21 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US20030194376A1 (en) * 1990-05-18 2003-10-16 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
AU636481B2 (en) * 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
US5447635A (en) * 1991-02-26 1995-09-05 Bracco International B.V. Process of concentration and purification of organic compounds
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
SE470086B (sv) * 1991-04-23 1993-11-08 Kabi Pharmacia Ab Organspecifik emulsion
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them
CA2146963A1 (en) * 1992-10-16 1994-04-28 Andreas Sachse Process and device for producing liquid, dispersed systems
PL182223B1 (pl) * 1993-12-15 2001-11-30 Bracco Research Sa Biokompatybilna faza rozproszona do otrzymywania srodka kontrastowego do badan ultradzwiekowych, srodek kontrastowy do badan ultradzwiekowych, suchy preparat srodka kontrastowego oraz dwuskladnikowy zestaw do otrzymywania srodka kontrastowego do badan ultradzwiekowych PL PL PL
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
AU736301B2 (en) 1996-05-01 2001-07-26 Imarx Therapeutics, Inc. Methods for delivering compounds into a cell
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
JP4109780B2 (ja) 1998-03-06 2008-07-02 株式会社東海理化電機製作所 ギヤ機構及びウエビング巻取装置
WO1999049849A1 (en) * 1998-03-31 1999-10-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal bupivacaine compositions and methods of preparation
JP3980777B2 (ja) 1998-11-02 2007-09-26 株式会社東海理化電機製作所 ウエビング巻取装置
US6426145B1 (en) 1999-05-20 2002-07-30 Scimed Life Systems, Inc. Radiopaque compositions for visualization of medical devices
JP2005170928A (ja) * 2003-10-21 2005-06-30 Konica Minolta Medical & Graphic Inc リポソーム含有ｘ線造影剤およびその製造方法
JP2005170923A (ja) * 2003-10-21 2005-06-30 Konica Minolta Medical & Graphic Inc リポソーム含有ｘ線造影剤およびその製造方法
JP4654590B2 (ja) * 2004-03-31 2011-03-23 コニカミノルタエムジー株式会社 Ｘ線ｃｔ用造影組成物およびその製造方法
US20060110439A1 (en) * 2004-10-22 2006-05-25 Dynamis Therapeutics, Inc. Dermal delivery of n-methyl-glucamine and n-methyl-glucamine compounds
AU2009257279A1 (en) * 2008-06-13 2009-12-17 Marval Biosciences, Inc. Imaging of atherosclerotic plaques using liposomal imaging agents
IT1404011B1 (it) 2010-12-03 2013-11-08 Uni Degli Studi Magna Graecia Di Catanzaro Nanovettore coniugato con tsh per il trattamento del cancro della tiroide
FR3017295B1 (fr) * 2014-02-07 2018-01-12 Guerbet Composition destinee a vectoriser un agent anticancereux
CN107206111B (zh) 2014-12-31 2021-04-27 蓝瑟斯医学影像公司 脂质封装的气体微球组合物及相关方法
FR3039767B1 (fr) 2015-08-04 2017-09-08 Guerbet Sa Composition destinee a vectoriser un agent anticancereux
CN109641068B (zh) 2016-05-04 2022-09-30 蓝瑟斯医学影像公司 用于制备超声波造影剂的方法及装置
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4192859A (en) * 1978-09-29 1980-03-11 E. R. Squibb & Sons, Inc. Contrast media containing liposomes as carriers
FR2437831A1 (fr) * 1978-10-05 1980-04-30 Daeniker Felix Agent de contraste pour l'examen radiologique du foie et procede pour sa preparation
US4599227A (en) * 1983-11-07 1986-07-08 Wisconsin Alumni Research Foundation Injectable pharmaceutical preparation for the induction of multiple follicular growth
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957971A (en) * 1974-07-29 1976-05-18 Lever Brothers Company Moisturizing units and moisturizing compositions containing the same
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4529561A (en) * 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
US4241046A (en) * 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4519024A (en) * 1983-09-02 1985-05-21 At&T Bell Laboratories Two-terminal transistor rectifier circuit arrangement
US4744989A (en) * 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
US4567034A (en) * 1984-09-07 1986-01-28 E. R. Squibb & Sons, Inc. Esters of diatrizoic acid as X-ray contrast agents
CH672733A5 (US06403056-20020611-C00020.png) * 1987-05-22 1989-12-29 Bracco Ind Chimica Spa

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4192859A (en) * 1978-09-29 1980-03-11 E. R. Squibb & Sons, Inc. Contrast media containing liposomes as carriers
FR2437831A1 (fr) * 1978-10-05 1980-04-30 Daeniker Felix Agent de contraste pour l'examen radiologique du foie et procede pour sa preparation
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4599227A (en) * 1983-11-07 1986-07-08 Wisconsin Alumni Research Foundation Injectable pharmaceutical preparation for the induction of multiple follicular growth

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658551A (en) * 1990-04-02 1997-08-19 Bracco International B.V. Stable microbubbles suspensions injectable into living organisms
US5271928A (en) * 1990-04-02 1993-12-21 Sintetica S.A. Stable microbubbles suspensions injectable into living organisms
US5380519A (en) * 1990-04-02 1995-01-10 Bracco International B.V. Stable microbubbles suspensions injectable into living organisms
US5531980A (en) * 1990-04-02 1996-07-02 Bracco International Bv Stable microbubbles suspensions injectable into living organisms
US6613306B1 (en) * 1990-04-02 2003-09-02 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US5567414A (en) * 1990-04-02 1996-10-22 Bracco International B.V. Stable microbubbles suspensions injectable into living organisms
US6110443A (en) * 1990-04-02 2000-08-29 Bracco International N.V. Dry stable formation to produce microbubble suspension for ultrasound
US5643553A (en) * 1990-04-02 1997-07-01 Bracco International B.V. Stable microbubbles suspensions injectable into living organisms
WO1992010166A1 (en) * 1990-12-11 1992-06-25 Sintetica S.A. Method for making liposomes of enhanced entrapping capacity toward foreign substances to be encapsulated
WO1992021384A1 (en) * 1991-06-03 1992-12-10 Karlshamns Lipidteknik Ab X-ray contrast agent
US5550263A (en) * 1991-06-03 1996-08-27 Karlshamns Lipidteknik Ab X-ray contrast agent
US5614214A (en) * 1993-05-21 1997-03-25 The Liposome Company, Inc. Reduction of liposome-induced adverse physiological reactions
US5662930A (en) * 1993-05-21 1997-09-02 The Liposome Company, Inc. Reduction of liposome-induced adverse physiological reactions
US6217849B1 (en) 1993-09-29 2001-04-17 Bracco Research S.A. Liposome suspensions as blood pool imaging contrast agents
US5676928A (en) * 1994-03-28 1997-10-14 Nycomed Imaging As Liposomes
WO1996025955A1 (en) * 1995-02-24 1996-08-29 Bracco Research S.A. Liposome suspensions as blood pool imaging contrast agents
US5874422A (en) * 1995-05-10 1999-02-23 Schering Aktiengesellschaft Use of non-steroidal anti-inflammatory agents to improve the physiological compatibility of particulate pharmaceutical preparations
WO1996035429A1 (de) * 1995-05-10 1996-11-14 Schering Aktiengesellschaft Verwendung nichtsteroidaler entzündungshemmer zur verbesserung der physiologischen verträglichkeit partikulärer pharmazeutischer zubereitungen
WO2000011007A1 (en) * 1998-08-19 2000-03-02 Bracco Research S.A. Carboxylated phosphatidic acid esters
US7468194B1 (en) 1999-05-27 2008-12-23 Euro-Celtique, S.A. Preparations for the application of anti-inflammatory agents
US7297344B1 (en) 1999-05-27 2007-11-20 Euro-Celtique, S.A. Preparations for the promotion of wound healing in the upper respiratory tract and/or ear
US7300667B1 (en) 1999-05-27 2007-11-27 Euro-Celtique, S.A. Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract
EP2279757A2 (en) 2000-06-02 2011-02-02 Bracco Suisse SA Compounds for targeting endothelial cells
EP2286843A2 (en) 2000-06-02 2011-02-23 Bracco Suisse SA Compounds for targeting endothelial cells
EP1742669A1 (en) * 2004-04-21 2007-01-17 Marvel Therapeutics Compositions and methods for enhancing contrast in imaging
EP1742669A4 (en) * 2004-04-21 2010-06-23 Marval Biosciences Inc COMPOSITIONS AND METHODS FOR ENHANCING CONTRAST IN IMAGING
US8911708B2 (en) 2004-04-21 2014-12-16 Marval Pharma, Inc. Nano-scale contrast agents and methods of use
USRE45195E1 (en) 2004-04-21 2014-10-14 Marval Pharma, Inc. Compositions and methods for enhancing contrast in imaging
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
EP2578237A1 (en) * 2004-04-21 2013-04-10 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US7588751B2 (en) * 2004-07-21 2009-09-15 Konica Minolta Medical & Graphic, Inc. Liposome-containing radiographic contrast medium and preparation method thereof
US8480952B2 (en) * 2004-08-11 2013-07-09 Konica Minolta Medical & Graphic, Inc. Method of manufacturing pharmaceutical preparations containing liposomes
WO2007129311A3 (en) * 2006-05-04 2008-01-31 Pan Sci Tech S A Nano-particles with contrast agents for diagnostic delivery system for x-ray and ct
WO2007129311A2 (en) * 2006-05-04 2007-11-15 Pan Sci Tech S.A. Nano-particles with contrast agents for diagnostic delivery system for x-ray and ct
US8642013B2 (en) 2007-12-05 2014-02-04 Ananth Annapragada Nano-scale contrast agents and methods of use
EP2410990A4 (en) * 2009-03-19 2015-05-20 Marval Biosciences Inc COMPOSITIONS AND METHODS FOR CONTRAST GAINING IN IMAGING
US12036294B2 (en) 2009-10-09 2024-07-16 Signablok, Inc. Spherical rHDLs for targeted imaging
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging

Also Published As

Publication number Publication date
AU612371B2 (en) 1991-07-11
EP0314764A1 (en) 1989-05-10
ES2009917A6 (es) 1989-10-16
MX9203271A (es) 1992-07-01
DE3874485T2 (de) 1993-03-11
CA1303978C (en) 1992-06-23
JPH02500192A (ja) 1990-01-25
IL86409A0 (en) 1988-11-15
EP0314764B2 (en) 2000-02-02
JP2619037B2 (ja) 1997-06-11
DE3874485T3 (de) 2000-09-14
ATE80294T1 (de) 1992-09-15
CH672733A5 (US06403056-20020611-C00020.png) 1989-12-29
US5445810A (en) 1995-08-29
IL86409A (en) 1991-12-12
DE3874485D1 (de) 1992-10-15
AU1805488A (en) 1988-12-21
ZA883449B (en) 1988-11-16
EP0314764B1 (en) 1992-09-09
US5626832A (en) 1997-05-06
US5312615A (en) 1994-05-17

Similar Documents

Publication Publication Date Title
US5312615A (en) Injectable opacifying composition containing liposomes of high encapsulation capacity for X-ray examinations
DE69527194T2 (de) Liposomen enthaltend ein röntgen- oder ultraschallkontrastmittel
DE68912139T2 (de) Liposomale radiologische kontrastmittel.
DE69230144T2 (de) Röntgenkontrastmittel
AU635456B2 (en) Method for making liposomes of enhanced entrapping capacity toward foreign substances to be encapsulated
JP3759765B2 (ja) リポソーム
US6217849B1 (en) Liposome suspensions as blood pool imaging contrast agents
JP2005170923A (ja) リポソーム含有ｘ線造影剤およびその製造方法
DE69616453T2 (de) Liposomensuspensionen als blut-pool-kontrastmittel
US4735795A (en) Alkylammonium complexes of diatrizoic acid as X-ray contrast agents
JPH10513466A (ja) 脈管内空間を視覚化するための造影剤を含むリポソーム
JP4649841B2 (ja) リポソーム含有製剤の製造方法、およびリポソーム含有製剤
EP1009445A2 (en) Particulate compositions
JP2008120721A (ja) 高比重薬剤を内包したリポソームの製造方法
JP2005179214A (ja) Ｘ線検査用造影剤
EP0726762A1 (en) Charged liposome preparation
JP2005145845A (ja) Ｘ線検査用造影剤
JP2005225791A (ja) リポソーム含有ｘ線検査用造影剤
JP2005170928A (ja) リポソーム含有ｘ線造影剤およびその製造方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR DK FI HU JP KP KR LK MC MG MW NO RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1988904952

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1988904952

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1988904952

Country of ref document: EP